PLS-123

a Btk inhibitor with antineoplastic activity; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 06/20/2015 - "Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma." 01/01/2018 - "Here, we have developed a novel irreversible BTK inhibitor, PLS-123, that has more potent and selective anti-tumor activity than ibrutinib in vitro and in vivo. " 01/01/2018 - "The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma."
2.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/01/2018 - "The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma."
3.	B-Cell Lymphoma (Lymphoma, B Cell) 06/20/2015 - "Taken together, Btk inhibitor PLS-123 suggested a new direction to pharmacologically modulate Btk function and develop novel therapeutic drug for B-cell lymphoma treatment. " 06/20/2015 - "Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma."
4.	Lymphoma (Lymphomas) 06/20/2015 - "In addition, PLS-123 dose-dependently attenuated BCR- and chemokine-mediated lymphoma cell adhesion and migration. "

1.	Chemokines
2.	Phosphotransferases (Kinase)
3.	Agammaglobulinaemia Tyrosine Kinase
4.	Everolimus
5.	ibrutinib